Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Márk Barok(University of Helsinki), Heikki Joensuu(Orion Corporation (Finland))

BMC Cancer

May 1, 2018

10.1186/s12885-018-4418-2

Cited by 81

Related Papers

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

|New England Journal of Medicine|2002|4.4k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

|New England Journal of Medicine|2006|1.4k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

|Annals of Oncology|2014|1.3k